Semaglutide Use Surges in US Adults With Diabetes Semaglutide Use Surges in US Adults With Diabetes

By the first quarter 2022, 57% of US adults with type 2 diabetes taking an incretin-based agent were taking a GLP-1 receptor agonist; DPP-4 inhibitor use fell to 39% of these scripts.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news